LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alcobra, Ltd. (“Alcobra” or the “Company”) (Nasdaq: ADHD). Investors, who purchased or otherwise acquired shares between August 13, 2015 and January 17, 2017 inclusive (the "Class Period") are encouraged to contact the Firm in advance of the April 18, 2017 lead plaintiff motion deadline.
If you are a shareholder who suffered a loss during the Class Period, click here. In addition, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at email@example.com.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Alcobra is a biopharmaceutical company that develops and markets oral drug candidates. On January 17, 2017, Alcobra revealed that the Company's attention deficit hyperactivity disorder drug, Metadoxine Extended Release, failed to reach its primary endpoint during a Phase 3 trial.
When this information was revealed to the investing public, the value of Alcobra declined, causing investors severe harm.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.